Immunohistochemical investigation of cytokine expression levels as biomarkers in transrectal ultrasound‑guided needle biopsy specimens of prostate adenocarcinoma

Singh,Jagtar; Thachil,Thanuja; Eapen,Mathew Suji; Lim,Aijye; Sufyan,Wajiha; Rawson,Robert; Duncan,Henry; De Ieso,Paolo; Sohal,Sukhwinder Singh

doi:10.3892/mco.2021.2353

Immunohistochemical investigation of cytokine expression levels as biomarkers in transrectal ultrasound‑guided needle biopsy specimens of prostate adenocarcinoma

Authors:
- Jagtar Singh
- Thanuja Thachil
- Mathew Suji Eapen
- Aijye Lim
- Wajiha Sufyan
- Robert Rawson
- Henry Duncan
- Paolo De Ieso
- Sukhwinder Singh Sohal
View Affiliations

Affiliations: College of Health and Human Sciences, Charles Darwin University, Northern Territory 0810, Australia, Ballarat Austin Radiation Oncology Centre, Victoria 3350, Australia, Department of Laboratory Medicine, School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Tasmania 7248, Australia, Department of Anatomical Pathology, Royal Darwin Hospital 0810, Australia, Urology Department, Darwin Private Hospital, Northern Territory 0810, Australia, Peter MacCallum Cancer Centre, Victoria 3000, Australia
Published online on: July 16, 2021 https://doi.org/10.3892/mco.2021.2353
Article Number: 191

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cytokines influence the biological behaviour of prostate cancer (PC) and may influence patient outcome and serve as useful prognostic biomarkers. The aim of the present study was to evaluate cytokine expression levels in prostatic needle biopsy specimens and the association with clinicopathological characteristics of patients with PC. A total of 18 patients with PC who underwent transrectal ultrasound (TRUS) guided prostate biopsy were included in the clinical study. These patients were naïve to radiotherapy (RT) or androgen deprivation therapy prior to TRUS biopsy and clinical follow up data was collected. Cytokine expression levels were analysed by using immunohistochemistry and Spearman's correlation test was used to determine the correlation between cytokine expression and clinicopathological characteristics. Expression levels of pro‑inflammatory TNF‑α and IL‑6 decreased as Gleason score (GS) increased; however, a statistically significant difference was not detected. A statically significant correlation was observed between needle biopsy specimen and pre‑RT plasma sample expression levels of pro‑inflammatory TNF‑α and IL‑6 (P=0.01 and P=0.05, respectively) and anti‑inflammatory TGF‑β1 (P=0.05). However, further studies are needed to confirm these results using a larger sample size to confirm the prognostic value of pro‑inflammatory TNF‑α and IL‑6 and anti‑inflammatory TGF‑β1 in patients with PC.

View Figures

View References

1	Mattiuzzi C and Lippi G: Current cancer epidemiology. J Epidemiol Glob Health. 9:217–222. 2019.PubMed/NCBI View Article : Google Scholar
2	D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ and Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280:969–974. 1998.PubMed/NCBI View Article : Google Scholar
3	Burke HB: Predicting clinical outcomes using molecular biomarkers. Biomark Cancer. 8:89–99. 2016.PubMed/NCBI View Article : Google Scholar
4	Milicevic N, Mrcela M, Galic J and Marjanovic K: Expression of proinflammatory cytokine interleukin-6 in tissue samples of human prostate obtained by needle biopsy. Pathol Res Pract. 211:865–870. 2015.PubMed/NCBI View Article : Google Scholar
5	Ma D, Zhou Z, Yang B, He Q, Zhang Q and Zhang XH: Association of molecular biomarkers expression with biochemical recurrence in prostate cancer through tissue microarray immunostaining. Oncol Lett. 10:2185–2191. 2015.PubMed/NCBI View Article : Google Scholar
6	Rodriguez-Berriguete G, Sanchez-Espiridion B, Cansino JR, Olmedilla G, Martinez-Onsurbe P, Sanchez-Chapado M, Paniagua R, Fraile B and Royuela M: Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-α signaling pathways in prostate cancer. Cytokine. 64:555–563. 2013.PubMed/NCBI View Article : Google Scholar
7	Deorukhkar A and Krishnan S: Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol. 80:1904–1914. 2010.PubMed/NCBI View Article : Google Scholar
8	Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C and Marberger MJ: Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 56:171–182. 2003.PubMed/NCBI View Article : Google Scholar
9	Poutahidis T, Rao VP, Olipitz W, Taylor CL, Jackson EA, Levkovich T, Lee CW, Fox JG, Ge Z and Erdman SE: CD4⁺ lymphocytes modulate prostate cancer progression in mice. Int J Cancer. 125:868–878. 2009.PubMed/NCBI View Article : Google Scholar
10	George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ and Kantoff PW: The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: Results from cancer and leukemia group B 9480. Clin Cancer Res. 11:1815–1820. 2005.PubMed/NCBI View Article : Google Scholar
11	Rubin P, Johnston CJ, Williams JP, McDonald S and Finkelstein JN: A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys. 33:99–109. 1995.PubMed/NCBI View Article : Google Scholar
12	Christensen E, Pintilie M, Evans KR, Lenarduzzi M, Menard C, Catton CN, Diamandis EP and Bristow RG: Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clin Cancer Res. 15:5576–83. 2009.PubMed/NCBI View Article : Google Scholar
13	Hoogland AM, Kweldam CF and van Leenders GJ: Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: A review. Biomed Res Int. 2014(341324)2014.PubMed/NCBI View Article : Google Scholar
14	Epstein JI, Allsbrook WC Jr, Amin MB and Egevad LL: ISUP Grading Committee. The 2005 International society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol. 29:1228–1242. 2005.PubMed/NCBI View Article : Google Scholar
15	Van der Kwast T, Bubendorf L, Mazerolles C, Raspollini MR, Van Leenders GJ, Pihl CG and Kujala P: Guidelines on processing and reporting of prostate biopsies: The 2013 update of the pathology committee of the European randomized study of screening for prostate cancer (ERSPC). Virchows Arch. 463:367–377. 2013.PubMed/NCBI View Article : Google Scholar
16	Gleason DF: Histologic grading of prostate cancer: A perspective. Hum Pathol. 23:273–279. 1992.PubMed/NCBI View Article : Google Scholar
17	Tagai EK, Miller SM, Kutikov A, Diefenbach MA, Gor RA, Al-Saleem T, Chen DYT, Fleszar S and Roy G: Prostate cancer patients' understanding of the gleason scoring system: Implications for shared decision-making. J Cancer Educ. 34:441–445. 2019.PubMed/NCBI View Article : Google Scholar
18	Epstein JI, Feng Z, Trock BJ and Pierorazio PM: Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: Incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 61:1019–1024. 2012.PubMed/NCBI View Article : Google Scholar
19	Zimmermann AK, Camenisch U, Rechsteiner MP, Bode-Lesniewska B and Rossle M: Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma. Cancer Cytopathol. 122:48–58. 2014.PubMed/NCBI View Article : Google Scholar
20	Kapoor P and Deshmukh R: VEGF: A critical driver for angiogenesis and subsequent tumor growth: An IHC study. J Oral Maxillofac Pathol. 16:330–337. 2012.PubMed/NCBI View Article : Google Scholar
21	Wu YS, Wu XB, Zhang N, Jiang GL, Yu Y, Tong SJ, Jiang HW, Mao SH, Na R and Ding Q: Evaluation of PSA-age volume score in predicting prostate cancer in Chinese population. Asian J Androl. 20:324–329. 2018.PubMed/NCBI View Article : Google Scholar
22	Pessoa R, Werahera PN and Kim FJ: Chapter 102-Prostate Cancer. In Abernathy's Surgical Secrets, 7th edition. Harken AH and Moore EE (eds). Elsevier, Philadelphia, PA, pp450-451, 2018.
23	Kır G, Seneldir H and Gumus E: Outcomes of Gleason score 3+4=7 prostate cancer with minimal amounts (<6%) vs. ≥6% of Gleason pattern 4 tissue in needle biopsy specimens. Ann Diagn Pathol. 20:48–51. 2016.PubMed/NCBI View Article : Google Scholar
24	Freedland SJ and Moul JW: Prostate specific antigen recurrence after definitive therapy. J Urol. 177:1985–1991. 2007.PubMed/NCBI View Article : Google Scholar
25	Doganavsargil B, Simsir A, Boyacioglu H, Cal C and Hekimgil M: A comparison of p21 and p27 immunoexpression in benign glands, prostatic intraepithelial neoplasia and prostate adenocarcinoma. BJU Int. 97:644–648. 2006.PubMed/NCBI View Article : Google Scholar
26	Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D Jr and Corey E: Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 97:1211–1216. 2003.PubMed/NCBI View Article : Google Scholar
27	Mauri D, Pentheroudakis G, Tolis C, Chojnacka M and Pavlidis N: Inflammatory prostate cancer: An underestimated paraneoplastic clinical manifestation. Urol Oncol. 23:318–322. 2005.PubMed/NCBI View Article : Google Scholar
28	Romero Otero J, Garcia Gomez B, Campos Juanatey F and Touijer KA: Prostate cancer biomarkers: An update. Urol Oncol. 32:252–260. 2014.PubMed/NCBI View Article : Google Scholar
29	Wu D, Ni J, Beretov J, Cozzi P, Willcox M, Wasinger V, Walsh B, Graham P and Li Y: Urinary biomarkers in prostate cancer detection and monitoring progression. Crit Rev Oncol Hematol. 118:15–26. 2017.PubMed/NCBI View Article : Google Scholar
30	Lilja H, Ulmert D and Vickers AJ: Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer. 8:268–278. 2008.PubMed/NCBI View Article : Google Scholar
31	Nassif AE and Tambara Filho R: Immunohistochemistry expression of tumor markers CD34 and P27 as a prognostic factor of clinically localized prostate adenocarcinoma after radical prostatectomy. Rev Col Bras Cir. 37:338–344. 2010.PubMed/NCBI View Article : Google Scholar : (In English, Portuguese).
32	Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM and Slawin KM: Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 10:1992–1999. 2004.PubMed/NCBI View Article : Google Scholar
33	Cansino Alcaide JR, Vera San Martin R, Rodriguez de Bethencourt Codes F, Bouraoui Y, Rodriguez Berriguete G, Oueslati R, Perez-Utrilla M, De la Pena Barthel J, Paniagua Gomez-Alvarez R and Royuela Garcia M: Prostatic specific antigen (PS), pro-inflammatory cytokines, and prostatic pathology (benign prostatic hyperplasia and cancer). Relationship with malignancy. Arch Esp Urol. 62:359–366. 2009.PubMed/NCBI View Article : Google Scholar : (In Spanish).
34	Epstein JI: An update of the Gleason grading system. J Urol. 183:433–440. 2010.PubMed/NCBI View Article : Google Scholar
35	Shen MM and Abate-Shen C: Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev. 24:1967–2000. 2010.PubMed/NCBI View Article : Google Scholar
36	Stock RG, Cesaretti JA, Hall SJ and Stone NN: Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int. 104:1631–1636. 2009.PubMed/NCBI View Article : Google Scholar
37	Michalaki V, Syrigos K, Charles P and Waxman J: Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 90:2312–2316. 2004.PubMed/NCBI View Article : Google Scholar
38	Gomes IM, Arinto P, Lopes C, Santos CR and Maia CJ: STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score. Urol Oncol. 32:53.e23–29. 2014.PubMed/NCBI View Article : Google Scholar
39	Rube CE, Palm J, Erren M, Fleckenstein J, Konig J, Remberger K and Rube C: Cytokine plasma levels: reliable predictors for radiation pneumonitis? PLoS One. 3(e2898)2008.PubMed/NCBI View Article : Google Scholar
40	Singh J, Sohal SS, Ahuja K, Lim A, Duncan H, Thachil T and De Ieso P: Levels of plasma cytokine in patients undergoing neoadjuvant androgen deprivation therapy and external beam radiation therapy for adenocarcinoma of the prostate. Ann Transl Med. 8(636)2020.PubMed/NCBI View Article : Google Scholar